{"id":55854,"date":"2023-04-14T23:06:19","date_gmt":"2023-04-14T21:06:19","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023\/"},"modified":"2023-04-14T23:06:19","modified_gmt":"2023-04-14T21:06:19","slug":"the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023\/","title":{"rendered":"The Beachbody Company, Inc. Approves Deloitte & Touche LLP as Auditor for Fiscal Year Ending December 31, 2023"},"content":{"rendered":"
\n

EL SEGUNDO, Calif.–(BUSINESS WIRE)–The Beachbody Company, Inc. (NYSE: BODY) (the “Company” or “Beachbody”), a leading subscription health and wellness company, today announced the completion of a competitive review of independent registered public accounting firms for the year ending December 31, 2023, whereby the Company invited several firms to participate in the process, including its current independent registered public accounting firm, Ernst & Young LLP (\u201cEY\u201d). On April 11, 2023, the Audit Committee of the Company\u2019s Board of Directors approved the engagement of Deloitte & Touche LLP (\u201cD&T\u201d) and will replace EY as the Company\u2019s independent registered public accounting firm for the year ending December 31, 2023, effective immediately. The review process was not related to any disagreement between the Company and EY.<\/p>\n

\nAbout BODi and The Beachbody Company, Inc.<\/b><\/p>\n

\nHeadquartered in Southern California, BODi is a leading digital fitness, nutrition, and mindset subscription company with over two decades of creating innovative content and nutritional supplements designed to support and enrich strong Health Esteem. The Beachbody Company, Inc. is the parent company of BODi. For more information, please visit TheBeachbodyCompany.com<\/a>.<\/p>\n

\nForward Looking Statements<\/b><\/p>\n

\nThis press release contains “forward-looking” statements pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995, which are statements other than historical fact or in the future tense. These statements include but are not limited to, statements regarding our business strategy, our plans, and our objectives and future operations.<\/p>\n

\nForward-looking statements are based upon various estimates and assumptions, as well as information known to us as of the date hereof, and are subject to risks and uncertainties. Accordingly, actual results could differ materially due to a variety of factors. You can identify these statements by the use of terminology such as “believe”, “plans”, “expect”, “will”, “should,” “could”, “estimate”, “anticipate,” \u201cupon\u201d or similar forward-looking terms. You should not rely on these forward-looking statements as they involve risks and uncertainties that may cause actual results to vary materially from the forward-looking statements.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Relations<\/b>
ICR, Inc.
\n
BeachbodyIR@icrinc.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

EL SEGUNDO, Calif.–(BUSINESS WIRE)–The Beachbody Company, Inc. (NYSE: BODY) (the “Company” or “Beachbody”), a leading subscription health and wellness company, today announced the completion of a competitive review of independent registered public accounting firms for the year ending December 31, 2023, whereby the Company invited several firms to participate in the process, including its current … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55854","6":"format-standard","7":"category-industry"},"yoast_head":"\nThe Beachbody Company, Inc. Approves Deloitte & Touche LLP as Auditor for Fiscal Year Ending December 31, 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Beachbody Company, Inc. Approves Deloitte & Touche LLP as Auditor for Fiscal Year Ending December 31, 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"EL SEGUNDO, Calif.–(BUSINESS WIRE)–The Beachbody Company, Inc. (NYSE: BODY) (the “Company” or “Beachbody”), a leading subscription health and wellness company, today announced the completion of a competitive review of independent registered public accounting firms for the year ending December 31, 2023, whereby the Company invited several firms to participate in the process, including its current ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-14T21:06:19+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"The Beachbody Company, Inc. Approves Deloitte & Touche LLP as Auditor for Fiscal Year Ending December 31, 2023\",\"datePublished\":\"2023-04-14T21:06:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023\\\/\"},\"wordCount\":351,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023\\\/\",\"name\":\"The Beachbody Company, Inc. Approves Deloitte & Touche LLP as Auditor for Fiscal Year Ending December 31, 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-04-14T21:06:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Beachbody Company, Inc. Approves Deloitte & Touche LLP as Auditor for Fiscal Year Ending December 31, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Beachbody Company, Inc. Approves Deloitte & Touche LLP as Auditor for Fiscal Year Ending December 31, 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023\/","og_locale":"en_US","og_type":"article","og_title":"The Beachbody Company, Inc. Approves Deloitte & Touche LLP as Auditor for Fiscal Year Ending December 31, 2023 - Pharma Trend","og_description":"EL SEGUNDO, Calif.–(BUSINESS WIRE)–The Beachbody Company, Inc. (NYSE: BODY) (the “Company” or “Beachbody”), a leading subscription health and wellness company, today announced the completion of a competitive review of independent registered public accounting firms for the year ending December 31, 2023, whereby the Company invited several firms to participate in the process, including its current ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-14T21:06:19+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"The Beachbody Company, Inc. Approves Deloitte & Touche LLP as Auditor for Fiscal Year Ending December 31, 2023","datePublished":"2023-04-14T21:06:19+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023\/"},"wordCount":351,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023\/","url":"https:\/\/pharma-trend.com\/en\/the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023\/","name":"The Beachbody Company, Inc. Approves Deloitte & Touche LLP as Auditor for Fiscal Year Ending December 31, 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-04-14T21:06:19+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/the-beachbody-company-inc-approves-deloitte-touche-llp-as-auditor-for-fiscal-year-ending-december-31-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"The Beachbody Company, Inc. Approves Deloitte & Touche LLP as Auditor for Fiscal Year Ending December 31, 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55854","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55854"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55854\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55854"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55854"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55854"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}